LIGHT-LTBR interaction interfering mAbs (Johns Hopkins University)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameLIGHT-LTBR interaction interfering mAbs (Johns Hopkins University)
Drug Alias NameLIGHT-lymphotoxin beta receptor interaction interfering mAbs (Johns Hopkins University)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 3 modulatorsTumor necrosis factor superfamily member 14 modulators
TargetsTumor necrosis factor receptor superfamily member 3Tumor necrosis factor superfamily member 14
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJohns Hopkins University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohns Hopkins Technology VenturesJohns Hopkins University
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A